Adachi M, Taki T, Ieki Y, Huang C L, Higashiyama M, Miyake M
Department of Thoracic Surgery, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan.
Cancer Res. 1996 Apr 15;56(8):1751-5.
As part of our evaluation of members of the transmembrane 4 super-family as possible prognostic predictors, we performed a retrospective study on the expression of the recently identified KAI1 gene by tumors of the lung. This gene, which is identical to CD82, suppresses tumor metastasis of prostate cancer, and its decreased expression may be involved in malignant progression. We used reverse transcription-PCR to analyze tumor tissues from 151 lung cancer patients; 74 tumors were stage I, 17 were stage II, and 60 were stage III. Our results indicate that while 35 patients had tumors in which the KAI1/CD82 gene was conserved (positive), 116 patients had tumors with reduced gene expression (negative). The overall survival rate of patients with KAI1/CD82-positive tumors was significantly higher than that of patients with KAI1/CD82-negative tumors (77.4% versus 38.5%; P=0.002). Furthermore, the overall survival rate of patients with KAI1/CD82-positive adenocarcinoma was also much higher than that of individuals whose adenocarcinoma had reduced KAI1/CD82 expression (73.4% versus 27.1%;P=0.009). Multivariate analysis with the Cox regression model indicated that KAII/CD82 positivity correlated best with the overall survival rate, except for lymph node status. Our data suggest that high KAII/CD82 gene expression by tumors of the lung may be associated with a good prognosis. These findings complement our earlier studies on MRP-1/CD9, another member of the transmembrane 4 superfamily, whose reduced expression in non-small cell lung cancer appears to be a factor of poor prognosis. This set of observations suggests that assessment of the expression status of KAI1/CD82 and MRP-1/CD9 by tumors may provide prognostic information on the clinical behavior of lung cancer.
作为我们对跨膜4超家族成员作为潜在预后预测指标评估的一部分，我们对肺癌肿瘤中最近发现的KAI1基因的表达进行了一项回顾性研究。该基因与CD82相同，可抑制前列腺癌的肿瘤转移，其表达降低可能与恶性进展有关。我们使用逆转录聚合酶链反应分析了151例肺癌患者的肿瘤组织；74例肿瘤为I期，17例为II期，60例为III期。我们的结果表明，35例患者的肿瘤中KAI1/CD82基因保守（阳性），116例患者的肿瘤基因表达降低（阴性）。KAI1/CD82阳性肿瘤患者的总生存率显著高于KAI1/CD82阴性肿瘤患者（77.4%对38.5%；P=0.002）。此外，KAI1/CD82阳性腺癌患者的总生存率也远高于KAI1/CD82表达降低的腺癌患者（73.4%对27.1%；P=0.009）。使用Cox回归模型进行多变量分析表明，除淋巴结状态外，KAII/CD82阳性与总生存率的相关性最佳。我们的数据表明，肺癌肿瘤中高KAII/CD82基因表达可能与良好的预后相关。这些发现补充了我们早期对跨膜4超家族的另一个成员MRP-1/CD9的研究，其在非小细胞肺癌中的表达降低似乎是预后不良的一个因素。这一系列观察结果表明，评估肿瘤中KAI1/CD82和MRP-1/CD9的表达状态可能为肺癌的临床行为提供预后信息。
